(CHIM), also known as human challenge studies, are a powerful and controversial tool in early vaccine development. In CHIM studies, healthy volunteers are deliberately exposed to a pathogen under tightly controlled conditions to assess vaccine safety, immunogenicity, and early efficacy. When executed ethically and scientifically, CHIMs can accelerate vaccine development timelines and reduce uncertainty ahead of large-scale trials. This article explores how CHIMs are integrated into Phase 1 or early Phase 2 studies, with an emphasis on trial design, risk mitigation, and global regulatory guidance.

What Is a CHIM Study?

• Participants are intentionally infected with a well-characterized pathogen (e.g., malaria, influenza, norovirus)
• Pathogen is administered after a vaccine candidate or placebo
• Endpoints include infection rate, symptom severity, immune response, and pathogen shedding

Why Use CHIM in Early Vaccine Trials?

• Predictive of field efficacy: Shortens development timelines
• Controlled setting: Allows for standardization of exposure and outcome measurement
• Small sample size: Can detect immunological signals in n = 30–50
• Cost-effective: Reduces need for large-scale Phase 2b/3 before candidate selection

Diseases Commonly Studied with CHIM

• Plasmodium falciparum (malaria)
• Influenza A and B
• RSV (Respiratory Syncytial Virus)
• Salmonella Typhi (typhoid)
• Shigella, Norovirus, Rhinovirus

Design Elements of CHIM Trials

1. Study Population

• Typically healthy adults aged 18–45 years
• Screened for risk factors, prior immunity, and co-morbidities

2. Vaccine Dosing

• Administered 2–4 weeks before challenge
• Placebo-controlled designs used to assess protective efficacy

3. Pathogen Challenge

• Standardized inoculum prepared under GMP or GMP-like conditions
• Delivered via nasal spray, oral capsule, injection, or mosquito bite

4. Quarantine and Monitoring

• Subjects housed in isolation units for 10–21 days post-challenge
• Regular clinical exams, PCR swabs, and biomarker assessments

5. Rescue Therapy

• Pre-specified antibiotics or antivirals administered upon symptom onset or after a set period

Primary Endpoints in CHIM Studies

• Infection rate: PCR positivity or culture-confirmed infection
• Symptom severity: Clinical scoring scales (e.g., diarrhea, fever, fatigue)
• Viral/bacterial load: Area-under-the-curve for shedding duration
• Immunogenicity: Antibody titers, T-cell responses

Ethical and Safety Considerations

1. Fully Informed Consent

• Explains risks of intentional infection, treatment plans, and long-term effects
• Uses plain language and multimedia aids

2. Risk Mitigation

• Use of attenuated or well-characterized challenge strains
• Quarantine facilities with emergency support

3. Independent Oversight

• Ethics Committees, Data Safety Monitoring Boards (DSMBs), and regulators review protocols
• Must adhere to Declaration of Helsinki and WHO CHIM ethical standards

Regulatory and Global Perspectives

FDA

• Permits CHIM under IND with extensive justification
• May accept efficacy data in lieu of Phase 3 for certain indications (e.g., anthrax, smallpox)

EMA

• Has approved multiple CHIM protocols for vaccines under PRIME or orphan designations
• Demands CHIM conducted in accredited quarantine centers

CDSCO

• Currently reviews CHIM proposals case-by-case
• Approval requires DCGI and Ethics Committee oversight

CHIM Case Study: Malaria Vaccine

A recent CHIM study for a malaria vaccine used aseptic, cryopreserved Plasmodium falciparum sporozoites delivered via mosquito bites. Volunteers were vaccinated and then exposed under observation. Time to parasitemia was measured and compared between groups. Results informed progression to Phase 2b field trials in endemic regions.

Best Practices for CHIM Execution

• Predefine stopping rules and emergency procedures
• Develop challenge agent production under strict quality controls
• Train quarantine unit staff in infection management
• Build participant support infrastructure (psychological, financial, logistical)